A comparison of bortezomib, cyclophosphamide, and dexamethasone (Vel-CD) chemotherapy without and with thalidomide (Vel-CTD) for the treatment of relapsed or refractory multiple myeloma

Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed–refractory multiple myeloma

(2011) Massimo Offidani et al.   ANNALS OF HEMATOLOGY

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

(2011) S. V. Rajkumar et al.   BLOOD

Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma

(2010) Jonathan L. Kaufman et al.   CANCER

Multiple myeloma in Korea: past, present, and future perspectives. Experience of the Korean Multiple Myeloma Working Party

(2010) Jae Hoon Lee et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Low-dose Acyclovir is Effective for Prevention of Herpes Zoster in Myeloma Patients Treated with Bortezomib: A Report from the Korean Multiple Myeloma Working Party (KMMWP) Retrospective Study

(2010) S. J. Kim et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma

(2009) Martin Kropff et al.   ANNALS OF HEMATOLOGY

Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study

(2009) Yeo-Kyeoung Kim et al.   ANNALS OF HEMATOLOGY

Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma

(2009) William I. Bensinger et al.   BRITISH JOURNAL OF HAEMATOLOGY

Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy

(2009) Vinay Chaudhry et al.   JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM

The use of novel agents in the treatment of relapsed and refractory multiple myeloma

(2009) J P Laubach et al.   LEUKEMIA

Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial

(2009) C B Reeder et al.   LEUKEMIA

Phase I-II Trial of Bortezomib Plus Oral Cyclophosphamide and Prednisone in Relapsed and Refractory Multiple Myeloma

(2008) Donna E. Reece et al.   JOURNAL OF CLINICAL ONCOLOGY